{"id":9104,"date":"2025-10-27T21:49:37","date_gmt":"2025-10-27T18:49:37","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9104"},"modified":"2025-10-27T21:49:37","modified_gmt":"2025-10-27T18:49:37","slug":"management-of-regular-wide-qrs-complex-tachycardias","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/management-of-regular-wide-qrs-complex-tachycardias\/","title":{"rendered":"Management of Regular Wide QRS Complex Tachycardias"},"content":{"rendered":"
Management of Regular Wide QRS Complex Tachycardias<\/div>\n
<\/div>\n
Presented at the Electrophysiology (EP) Session, Jordan Cardiac Society (JCS) Taskforce Congress, 2025<\/div>\n
<\/div>\n
Speaker: Dr. Laith Saleh, Interventional Electrophysiologist<\/div>\n
Reference: Based on AHA\/ESC 2023\u20132025 Tachyarrhythmia Algorithms and Advanced Life Support Guidelines.<\/div>\n
<\/div>\n
Keynotes :<\/div>\n
\u20071.\u2060 \u2060Overview and Clinical Challenge<\/div>\n
\u2022 Wide QRS Complex Tachycardia (WCT) represents one of the most critical emergency arrhythmias encountered in acute care.<\/span><\/div>\n
\u2022 The key difficulty: distinguishing VT from SVT with aberrancy, as diagnostic algorithms are complex and sometimes unreliable.<\/span><\/div>\n
\u2022 Rapid deterioration is possible, particularly with VT, so a structured algorithmic approach is essential for safe and timely management .<\/span><\/div>\n
<\/div>\n
\u20072.\u2060 \u2060Step 1 \u2013 Determine Regularity and QRS Width<\/div>\n
\u2022 First visual step: assess whether the rhythm is regular or irregular (ECG examples shown on slides 6\u20137).<\/span><\/div>\n
\u2022 Then evaluate if the QRS complex is narrow (<120 ms) or wide (\u2265120 ms) \u2014 the latter mandates urgent evaluation for VT until proven otherwise .<\/span><\/div>\n
<\/div>\n
\u20073.\u2060 \u2060\u201cWord of Caution\u201d \u2013 When to Prepare for Shock<\/div>\n
\u2022 If the rhythm is irregular with variable QRS morphology, consider:<\/span><\/div>\n
\u2022 Polymorphic VT, or<\/span><\/div>\n
\u2022 Atrial fibrillation with WPW (pre-excitation).<\/span><\/div>\n
\u2022 Immediate preparation for defibrillation and expert help is warranted in these cases .<\/span><\/div>\n
<\/div>\n
\u20074.\u2060 \u2060Hemodynamic Assessment<\/div>\n
\u2022 Management depends on hemodynamic stability, not ECG appearance alone.<\/span><\/div>\n
\u2022 Unstable patients: hypotension, chest pain, altered consciousness, or shock.<\/span><\/div>\n
\u2022 Stable patients: maintained blood pressure and perfusion despite tachycardia.<\/span><\/div>\n
\u2022 Always ensure team-based evaluation and continuous monitoring .<\/span><\/div>\n
<\/div>\n
\u20075.\u2060 \u2060Immediate Cardioversion for Unstable WCT<\/div>\n
\u2022 For unstable but conscious patients:<\/span><\/div>\n
\u2022 Perform synchronized cardioversion.<\/span><\/div>\n
\u2022 Use sedation and analgesia if feasible.<\/span><\/div>\n
\u2022 Select shock type based on ECG pattern (monomorphic vs polymorphic VT) .<\/span><\/div>\n
<\/div>\n
\u20076.\u2060 \u2060Diagnostic Approach in Stable Patients<\/div>\n
\u2022 Obtain 12-lead ECG and record rhythm strips.<\/span><\/div>\n
\u2022 Attempt vagal maneuvers or adenosine if the tachycardia is regular and monomorphic \u2014 these can provide both diagnostic and therapeutic benefit.<\/span><\/div>\n
\u2022 Always record the ECG during the maneuver to capture changes .<\/span><\/div>\n
<\/div>\n
\u20077.\u2060 \u2060Vagal Maneuvers \u2013 Dual Role<\/div>\n
\u2022 Diagnostic: may unmask underlying atrial activity (flutter, AT).<\/span><\/div>\n
\u2022 Therapeutic: can terminate AV node\u2013dependent SVTs (AVNRT, AVRT).<\/span><\/div>\n
\u2022 Ineffective in most cases of VT, though may reveal AV dissociation (helpful diagnostically).<\/span><\/div>\n
\u2022 Examples: Valsalva maneuver, carotid sinus massage (with caution in elderly or carotid disease) .<\/span><\/div>\n
<\/div>\n
8.\u00a0 \u00a0 Adenosine Use \u2013 Indications and Caution<\/div>\n
\u2022 Can terminate:<\/span><\/div>\n
\u2022 AVNRT, AVRT, and some idiopathic VTs (notably RVOT VT).<\/span><\/div>\n
\u2022 Helps differentiate SVT with aberrancy from VT if response is diagnostic.<\/span><\/div>\n
\u2022 Must always be given with resuscitation equipment ready due to risk of transient asystole or worsening conduction in pre-excitation .<\/span><\/div>\n
<\/div>\n
\u20079.\u2060 \u2060If Rhythm Persists \u2013 Treat as VT<\/div>\n
\u2022 When etiology remains uncertain after initial interventions, always treat as VT.<\/span><\/div>\n
\u2022 Continue monitoring, initiate antiarrhythmic infusion (amiodarone or procainamide), and avoid AV nodal blockers until diagnosis is certain .<\/span><\/div>\n
<\/div>\n
10.\u2060 \u2060Pharmacologic Cardioversion in VT<\/div>\n
\u2022 Amiodarone:<\/span><\/div>\n
\u2022 150 mg IV over 10 min \u2192 then 1 mg\/min for 6 h.<\/span><\/div>\n
\u2022 Procainamide:<\/span><\/div>\n
\u2022 20\u201350 mg\/min infusion \u2192 stop when rhythm converts or 15 mg\/kg max reached.<\/span><\/div>\n
\u2022 Both may cause hypotension; close hemodynamic and ECG monitoring is mandatory .<\/span><\/div>\n
<\/div>\n
11.\u2060 \u2060Special Considerations<\/div>\n
\u2022 Idiopathic VT (structurally normal heart):<\/span><\/div>\n
\u2022 May respond to \u03b2-blockers or calcium-channel blockers.<\/span><\/div>\n
\u2022 Underlying cardiac disease:<\/span><\/div>\n
\u2022 Correct ischemia, heart failure, electrolytes, and drug toxicity before further interventions .<\/span><\/div>\n
<\/div>\n
12.\u2060 \u2060Stepwise Management of SVT (Algorithm Summary)<\/div>\n
1. Vagal maneuvers.<\/span><\/div>\n
2. Adenosine (if regular and monomorphic).<\/span><\/div>\n
3. IV beta-blocker or calcium-channel blocker.<\/span><\/div>\n
4. Electrical cardioversion if refractory.<\/span><\/div>\n
(Flowchart displayed on slides 24\u201325 mirrors AHA ACLS 2020 and ESC 2022 updates.) .<\/div>\n
<\/div>\n
13.\u2060 \u2060WCT in Patients with Pacemakers or ICDs<\/div>\n
\u2022 Pacemaker patients:<\/span><\/div>\n
\u2022 WCT may result from tracking atrial arrhythmia or pacemaker-mediated tachycardia.<\/span><\/div>\n
\u2022 Magnet application sets device to asynchronous pacing (VOO\/DOO), terminating PMT.<\/span><\/div>\n
\u2022 ICD patients:<\/span><\/div>\n
\u2022 Always assume VT until proven otherwise.<\/span><\/div>\n
\u2022 If multiple shocks occur without resolution \u2192 suspect VT storm or lead malfunction.<\/span><\/div>\n
\u2022 Magnet suspends shocks but does not stop pacing .<\/span><\/div>\n
<\/div>\n
14.\u2060 \u2060Recurrent or Persistent WCT<\/div>\n
\u2022 Reassess triggers: ischemia, electrolytes, toxicity.<\/span><\/div>\n
\u2022 Reattempt cardioversion or give amiodarone infusion for suppression.<\/span><\/div>\n
\u2022 Seek EP consultation for resistant or recurrent arrhythmias .<\/span><\/div>\n
<\/div>\n
15.\u2060 \u2060Long-Term Management<\/div>\n
\u2022 For VT:<\/span><\/div>\n
\u2022 Evaluate for ICD implantation if no reversible cause.<\/span><\/div>\n
\u2022 Ablation to reduce recurrent VT episodes.<\/span><\/div>\n
\u2022 For SVT:<\/span><\/div>\n
\u2022 Manage per guideline-based therapy (rate\/rhythm control, ablation if recurrent).<\/span><\/div>\n
\u2022 Idiopathic VT:<\/span><\/div>\n
\u2022 Treated effectively with ablation or medical therapy, not ICD .<\/span><\/div>\n
<\/div>\n
16.\u2060 \u2060Take-Home Message<\/div>\n
<\/div>\n
\u201cIn any regular wide complex tachycardia of uncertain origin \u2014 always assume VT until proven otherwise.<\/div>\n
Simplicity, safety, and structured teamwork save lives.\u201d<\/div>\n","protected":false},"excerpt":{"rendered":"

Management of Regular Wide QRS Complex Tachycardias Presented at the Electrophysiology (EP) Session, Jordan Cardiac Society (JCS) Taskforce Congress, 2025 Speaker: Dr. Laith Saleh, Interventional Electrophysiologist Reference: Based on AHA\/ESC 2023\u20132025 Tachyarrhythmia Algorithms and Advanced Life Support Guidelines. Keynotes : \u20071.\u2060 \u2060Overview and Clinical Challenge \u2022 Wide QRS Complex Tachycardia (WCT) represents one of the […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9104","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9104"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9104\/revisions"}],"predecessor-version":[{"id":9105,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9104\/revisions\/9105"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9104"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9104"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}